Roles of KLF6 and KLF6-SV1 in ovarian cancer progression and intraperitoneal dissemination

Clinical Cancer Research

Volumn 12, Issue 12, 2006, Pages 3730-3739

  DiFeo, Analisa ^a   Narla, Goutham ^a   Hirshfeld, Jennifer ^a   Camacho Vanegas, Olga ^a   Narla, Jyothsna ^b   Rose, Stephen L ^c   Kalir, Tamara ^a   Yao, Shen ^a   Levine, Alice ^a   Birrer, Michael J ^d   Bonome, Tomas ^d   Friedman, Scott L ^a   Buller, Richard E ^c,e   Martignetti, John A ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b Regional Medical Center   (United States)

^c UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; PROTEIN KLF6; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER STAGING; CELL INVASION; CELL PROLIFERATION; DNA SEQUENCE; DOWN REGULATION; FEMALE; GENE SILENCING; HETEROZYGOSITY LOSS; HUMAN; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION;

ADENOCARCINOMA; DISEASE PROGRESSION; DNA, NEOPLASM; FEMALE; GENETIC MARKERS; HUMANS; KRUPPEL-LIKE TRANSCRIPTION FACTORS; LOSS OF HETEROZYGOSITY; NEOPLASM, RESIDUAL; OVARIAN NEOPLASMS; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS; RNA, NEOPLASM; RNA, SMALL INTERFERING;

EID: 33745725772     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-0054     Document Type: Article

References (40)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
2. Ozols RF, Bookman MA, Connolly DC, et al. Focus on epithelial ovarian cancer. Cancer Cell 2005;5:19-24.
3. Bieker JJ. Kruppel-like factors: three fingers in many pies. J Biol Chem 2001;276:34355-8.
4. Black AR, Black JD, Azizkhan-Clifford J. Sp1 and Kruppel-like factor family of transcription factors in cell growth regulation and cancer. J Cell Physiol 2001;188:143-60.
5. Narla G, Heath KE, Reeves HL, et al. KLF6, a candidate tumor suppressor gene mutated in prostate cancer. Science 2001;294:2563-6.
6. Chen C, Hyytinen ER, Sun X, et al. Deletion, mutation, and loss of expression of KLF6 in human p rostate cancer. Am J Pathol 2003;162:1349-54.
7. Reeves HL, Narla G, Ogunbiyi O, et al. Kruppel-like factor 6 (KLF6) is a tumor suppressor gene frequently inactivated in colorectal cancer. Gastroenterology 2004;126:1090-103.
8. Ito G, Uchiyama M, Kondo M, et al. Kruppel-like factor 6 is frequently down-regulated and induces apoptosis in non-small cell lung cancer cells. Cancer Res 2004;64:3838-43.
9. Cho YG, Kim CJ, Park CH, et al. Genetic alterations of the KLF6 gene in gastric cancer. Oncogene 2005;24:4588-90.
10. Jeng YM, Hsu HC. KLF6, a putative tumor suppressor gene, is mutated in astrocytic gliomas. Int J Cancer 2003;105:625-9.
11. Chen HK, Liu XQ, Lin J, et al. Mutation analysis of KLF6 gene in human nasopharyngeal carcinomas. Ai Zheng 2002;21:1047-50.
12. Tal-Kremer S, Reeves HL, Narla G, et al. Frequent inactivation of the tumor suppressor Kruppel-like factor 6 (KLF6) in hepatocellular carcinoma. Hepatology 2004;40:1047-52.
13. Wang S, Chen X, Zhang W, Qiu F. KLF6mRNA expression in primary hepatocellular carcinoma. J Huazhong Univ Sci Technol Med Sci 2004;24:585-7.
14. Glinsky GV, Glinskii AB, Stephenson AJ, Hoffman RM, Gerald WI. Gene expression profiling predicts clinical outcome of prostate cancer. J Clin Invest 2004;113:913-23.
15. Singh D, Febbo PG, Ross K, et al. Gene expression correlates of clinical prostate cancer behavior. Cancer Cell 2002;2:203-9.
16. Kettunen E, Anttila S, Seppanen JK, et al. Differentially expressed genes in nonsmall cell lung cancer: expression profiling of cancer-related genes in squamous cell lung cancer. Cancer Genet Cytogenet 2004;149:98-106.
17. Kimmelman AC, Qiao RF, Narla G, et al. Suppression of glioblastoma by the Kruppel-like transcription factor 6, KLF6. Oncogene 2004;23:5077-83.
18. Benzeno S, Narla G, Allina J, et al. Cyclin-dependent kinase inhibition by the KLF6 tumor suppressor protein through interaction with cyclin D1. Cancer Res 2004;64:3885-91.
19. Slavin DA, Koritschoner NP, Prieto CC, et al. A new role for the Kruppel-like transcription factor KLF6 as an inhibitor of c-jun proto-oncoprotein function. Oncogene 2004;23:8196-205.
20. Narla G, DiFeo A, Reeves HL, et al A germline DNA polymorphism associated with increased prostate cancer risk enhances alternative splicing of the KLF6 tumor suppressor gene. Cancer Res 2005;65:1213-22.
21. Narla G, DiFeo A, Yao S, et al. Targeted inhibition of the KLF6 splice variant, KLF6 SV1, suppresses prostate cancer cell growth and spread. Cancer Res 2005;65:5761-8.
22. Skilling JS, Sood A, Niemann T, Lager DJ, Buller RE. An abundance of p53 null mutations in ovarian carcinoma. Oncogene 1996;13:117-23.
23. Bamberger ES, Perrett CW. Angiogenesis in epithelial ovarian cancer. Mol Pathol 2002;55:348-59.
24. Zorn KK, Jazaeri AA, Awtrey CS, et al. Choice of normal ovarian control influences determination of differentially expressed genes in ovarian cancer expression profiling studies. Clin Cancer Res 2003;13:4811-8.
25. Bonome T, Lee JY, Park DC, et al. Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Res 2005;22:10602-12.
26. Shih SC, Robinson GS, Perruzzi CA, et al. Molecular profiling of angiogenesis markers. Am J Pathol 2002;161:35-41.
27. Mesiano S, Ferrara N, Jaffe RB. Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization. Am J Pathol 1998;153:1249-56.
28. Hashimoto K, Morishige K, Sawada K, et al. Alendronate inhibits intraperitoneal dissemination in in vivo ovarian cancer model. Cancer Res 2005;65:540-5.
29. Verheul HM, Pinedo HM. The role of vascular endothelial growth factor (VEGF) in tumor angiogenesis and early clinical development of VEGF-receptor kinase inhibitors. Clin Breast Cancer 2000;1: S80-4.
30. Yamashita K, Upadhyay S, Osada M, et al. Pharmacologic unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma. Cancer Cell 2002;2:485-95.
31. Macleod K, Mullen P, Sewell J, et al. Altered ErbB receptor signaling and gene expression in cisplatin-resistant ovarian cancer. Cancer Res 2005;65:6789-800.
32. Okada S, Tsuda H, Takarabe T, et al. Allelotype analysis of common epithelial ovarian cancers with special reference to comparison between clear cell adenocarcinoma with other histological types. Jpn J Cancer Res 2002;93:798-806.
33. Schwartz DR, Kardia SL, Shedden KA, et al. Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Res 2002;62:4722-9.
34. Tsuchiya A, Sakamoto M, Yasuda J, et al. Expression profiling in ovarian clear cell carcinoma: identification of hepatocyte nuclear factor-1β as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma. Am J Pathol 2003;163:2503-12.
35. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-64.
36. Folkman J, D'Amore PA. Blood vessel formation: what is its molecular basis? Cell 1996;87:1153-5.
37. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000;407:249-57.
38. Yamamoto S, Konishi I, Mandai M, et al. Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathology and patient survival, and analysis of serum VEGF levels. Br J Cancer 1997;76:1221-7.
39. Weis SM, Cheresh DA. Pathophysiological consequences of VEGF-induced vascular permeability. Nature 2005;437:497-504.
40. Kim KJ, Li B, Winer J. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993;362:841-4.